Zacks Research Issues Positive Estimate for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Stock analysts at Zacks Research raised their Q1 2025 earnings estimates for Bausch Health Companies in a report released on Monday, January 20th. Zacks Research analyst R. Department now forecasts that the company will earn $0.87 per share for the quarter, up from their prior estimate of $0.85. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $1.04 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.15 EPS and Q3 2026 earnings at $1.38 EPS.

Several other research firms also recently commented on BHC. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Finally, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.75.

Bausch Health Companies Price Performance

NYSE BHC opened at $7.73 on Wednesday. The stock’s 50 day simple moving average is $7.86 and its 200-day simple moving average is $7.45. The company has a market cap of $2.79 billion, a PE ratio of -16.09 and a beta of 0.69. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The company’s revenue for the quarter was up 12.2% on a year-over-year basis.

Hedge Funds Weigh In On Bausch Health Companies

A number of institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its holdings in Bausch Health Companies by 12.1% in the second quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock valued at $22,063,000 after acquiring an additional 341,936 shares during the last quarter. Seven Eight Capital LP acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $173,000. Maverick Capital Ltd. purchased a new position in shares of Bausch Health Companies during the 2nd quarter worth $1,606,000. The Manufacturers Life Insurance Company increased its position in shares of Bausch Health Companies by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock worth $1,719,000 after purchasing an additional 4,944 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after buying an additional 1,252,834 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.